iData Insights

Refractory Multiple Myeloma - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Dec 01, 2015 16:28 IST

Refractory Multiple Myeloma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Refractory Multiple Myeloma - Pipeline Review, H2 2015, provides an overview of the Refractory Multiple Myelomas therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC @

To Get Sample Copy of Report visit @

Table of Contents

Table of Contents

2 List of Tables

6 List of Figures

8 Introduction

9 Global Markets Direct Report Coverage

9 Refractory Multiple Myeloma Overview

10 Therapeutics Development

11 Pipeline Products for Refractory Multiple Myeloma - Overview

11 Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis

12 Refractory Multiple Myeloma - Therapeutics under Development by Companies

13 Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes

18 Refractory Multiple Myeloma - Pipeline Products Glance

19 Late Stage Products

19 Clinical Stage Products

20 Early Stage Products

21 Refractory Multiple Myeloma - Products under Development by Companies

22 Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes

27 Refractory Multiple Myeloma - Companies Involved in Therapeutics Development

28 4SC AG

28 AbbVie Inc.

29 Acetylon Pharmaceuticals, Inc.

30 Altor BioScience Corporation

31 Arno Therapeutics, Inc.

32 Array BioPharma Inc.

33 Astellas Pharma Inc.

34 Astex Pharmaceuticals, Inc.

35 Biotest AG

36 Boehringer Ingelheim GmbH

37 Bristol-Myers Squibb Company

38 Calithera Biosciences, Inc.

39 Celgene Corporation

40 Cellectar Biosciences, Inc.

41 Cleave Biosciences

42 CureTech Ltd.

43 Curis, Inc.

44 Dicerna Pharmaceuticals, Inc.

45 Exelixis, Inc.

46 F. Hoffmann-La Roche Ltd.

47 GlaxoSmithKline Plc

48 Immunomedics, Inc.

49 Jasco Pharmaceuticals, LLC.

50 Johnson & Johnson

51 JW Pharmaceutical Corporation

52 Karyopharm Therapeutics, Inc.

53 MedImmune, LLC

54 Merck & Co., Inc.

55 Millennium Pharmaceuticals, Inc.

56 MorphoSys AG

57 Novartis AG 58 Oncolytics Biotech Inc.

59 Oncopeptides AB

60 Onyx Pharmaceuticals, Inc.

61 Otsuka Holdings Co., Ltd.

62 Patrys Limited 63 Pfizer Inc.

64 Pharma Mar, S.A.

65 Prolexys Pharmaceuticals, Inc.

66 Sanofi

67 Sigma-Tau S.p.A.

68 Stemline Therapeutics, Inc.

69 Sumitomo Dainippon Pharma Co., Ltd.

70 Synta Pharmaceuticals Corp.

71 Threshold Pharmaceuticals, Inc.

72 Vivolux AB

73 Refractory Multiple Myeloma - Therapeutics Assessment

74 Assessment by Monotherapy Products

74 Assessment by Combination Products

75 Assessment by Target

76 Assessment by Mechanism of Action

81 Assessment by Route of Administration

85 Assessment by Molecule Type

87 Drug Profiles

89 4SC-202 - Drug Profile

89 ABBV-838 - Drug Profile

91 ACP-196 - Drug Profile

92 ACY-241 - Drug Profile

95 afuresertib hydrochloride - Drug Profile

97 alisertib - Drug Profile

99 alpelisib - Drug Profile

103 ALT-801 - Drug Profile

105 ALT-803 - Drug Profile

108 amrubicin hydrochloride - Drug Profile

110 AR-42 - Drug Profile

112 AT-7519 - Drug Profile

114 AT-9283 - Drug Profile

117 B-701 - Drug Profile

119 bendamustine hydrochloride - Drug Profile

120 BI-836909 - Drug Profile

123 BMS-986016 - Drug Profile

124 cabozantinib s-malate - Drug Profile

125 carfilzomib - Drug Profile

129 CB-5083 - Drug Profile

133 CB-839 - Drug Profile

134 CC-90002 - Drug Profile

136 Cell Therapy to Target CD

138 for Relapsed and Refractory Multiple Myeloma - Drug Profile

137 CUDC-907 - Drug Profile

138 CWP-291 - Drug Profile

140 daratumumab - Drug Profile

142 DCRM-1711 - Drug Profile

145 DKN-01 - Drug Profile

147 elotuzumab - Drug Profile

149 erismodegib - Drug Profile

151 evofosfamide - Drug Profile

154 filanesib - Drug Profile

161 ganetespib - Drug Profile

163 GSK-2857916 - Drug Profile

167 I131-CLR1404 - Drug Profile

168 ibrutinib - Drug Profile

170 indatuximab ravtansine - Drug Profile

177 inebilizumab - Drug Profile

179 ipilimumab - Drug Profile

181 isatuximab - Drug Profile

185 ixazomib citrate - Drug Profile

187 JP-11646 - Drug Profile

191 LCL-161 - Drug Profile

192 linsitinib - Drug Profile

194 marizomib - Drug Profile

196 Melflufen - Drug Profile

198 milatuzumab - Drug Profile

200 MOR-202 - Drug Profile

202 MV-NIS - Drug Profile

204 NL-101 - Drug Profile

206 OPB-51602 - Drug Profile

207 oprozomib - Drug Profile

208 palbociclib - Drug Profile

210 PATSM-6 - Drug Profile

214 pelareorep - Drug Profile

216 pembrolizumab - Drug Profile

221 pidilizumab - Drug Profile

230 PIM-447 - Drug Profile

232 plerixafor - Drug Profile

233 plitidepsin - Drug Profile

235 PRLX-93936 - Drug Profile

237 Recombinant Protein for Oncology - Drug Profile

239 ricolinostat - Drug Profile

241 roneparstat - Drug Profile

243 RRX-001 - Drug Profile

244 sapanisertib - Drug Profile

246 selinexor - Drug Profile

248 SL-401 - Drug Profile

254 trametinib dimethyl sulfoxide + uprosertib - Drug Profile

256 ulocuplumab - Drug Profile

258 urelumab - Drug Profile

260 vemurafenib - Drug Profile

262 venetoclax - Drug Profile

266 VLX-1570 - Drug Profile

269 vorinostat - Drug Profile

271 Refractory Multiple Myeloma - Recent Pipeline Updates

275 Refractory Multiple Myeloma - Dormant Projects

443 Refractory Multiple Myeloma - Discontinued Products

447 Refractory Multiple Myeloma - Product Development Milestones

448 Featured News & Press Releases

448 Appendix 456 Methodology

456 Coverage

456 Secondary Research

456 Primary Research

456 Expert Panel Validation

456 Contact Us

456 Disclaimer

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

Contact Us:
iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.